OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDERGOING ENTECAVIR OR TENOFOVIR TREATMENT

被引：0
|
作者：
Lee, Chieh-Ju [1 ]
Su, Chien-Wei [1 ,2 ]
Lin, Han-Chieh [1 ,2 ,3 ]
Hou, Ming-Chih [1 ,2 ,3 ]
Huang, Yi-Hsiang [1 ,2 ,3 ]
机构：
[1] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan
[2] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan
[3] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
944
引用
收藏
页码：578A / 579A
页数：2
相关论文
共 50 条
  • [21] Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?
    van Velsen, Lisa M.
    Sonneveld, Milan J.
    van Erpecum, Karel J.
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (06) : 919 - 922
  • [22] Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir
    Yu, Jung Hwan
    Suh, Young Ju
    Jin, Young-Joo
    Heo, Nae-Yun
    Jang, Ji Woong
    You, Chan Ran
    An, Hyun Young
    Lee, Jin-Woo
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (07) : 865 - 872
  • [23] Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum, Karel J.
    Sonneveld, Milan J.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 89 : 27 - 29
  • [24] Hepatitis B: Tenofovir is superior than Entecavir for treating Patients with Hepatocellular Carcinoma
    Lorenz, Judith
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (08):
  • [25] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    [J]. HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1083 - 1092
  • [26] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Chang, Jin Won
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Seo, Yeon Seok
    Lee, Han Ah
    Kim, Mi Na
    Lee, Yu Rim
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Um, Soon Ho
    Tak, Won Young
    Kweon, Young Oh
    Park, Soo Young
    Kim, Seung Up
    [J]. JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 95 - 104
  • [27] Lower risk of hepatocellular carcinoma among patients with chronic hepatitis B treated with tenofovir than entecavir
    Young-Suk Lim
    [J]. Cancer Biology & Medicine, 2018, (S1) : 19 - 20
  • [28] No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir
    Su, Feng
    Berry, Kristin
    Ioannou, George N.
    [J]. GUT, 2021, 70 (02) : 370 - 378
  • [29] Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir? Reply
    Yip, Terry Cheuk-Fung
    Wong, Grace Lai-Hung
    [J]. GASTROENTEROLOGY, 2020, 158 (08) : 2312 - 2313
  • [30] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee
    Young Youn Cho
    Hyein Lee
    Jae Seung Lee
    Seung Up Kim
    Jun Yong Park
    Do Young Kim
    Sang Hoon Ahn
    Beom Kyung Kim
    Soo Young Park
    [J]. Hepatology International, 2021, 15 : 1083 - 1092
12345